The effect of quercetin supplementation on antioxidant and inflammatory factors after the exhaustive progressive aerobic exercise in premenstrual syndrome in active young females

Start Date10 Nov 2024

Sponsor / Collaborator

Alzahra University

NCT06650891

/ CompletedPhase 3IIT

The Adjunctive Effect of Quercetin on Postoperative Pain Management Following Cesarean Section

The cesarean section is a common gynecological surgery, requiring effective pain management to prevent complications and immobility. Inadequate pain control can lead to longer hospital stays, higher readmission rates, and dissatisfaction with healthcare. Traditional analgesics, such as opioids, have proven effective in alleviating pain, but they can cause side effects. Therefore, researchers are exploring compounds that can reduce opioid analgesic needs and improve pain control. Quercetin has anti-nociceptive effects in rodent models of chronic pain, including inflammatory, neuropathic, and cancer pain. There are limited clinical studies on the effect of quercetin on acute or chronic pain. The current study is designed to assess the efficacy of preoperative quercetin administration in acute post-operative pain following cesarean section.

Start Date30 Oct 2024

Sponsor / Collaborator

Future University in Egypt

100 Clinical Results associated with Quercetin

100 Translational Medicine associated with Quercetin

100 Patents (Medical) associated with Quercetin

68,908

Literatures (Medical) associated with Quercetin

31 Dec 2025·Renal Failure

Efficacy and potential pharmacological mechanism of Astragalus-Salvia miltiorrhiza combination in diabetic nephropathy: integrating meta-analysis, network pharmacology, molecular docking, and experimental validation

Article

Author: Chen, Zedong ; Xiao, Ya ; Zhao, Xiaoshan ; Zhu, Mingmin ; Jiang, Pingping ; Zhong, Jingying ; Yuan, Jing ; Chen, Jianfeng ; Liang, Huiyu ; Lin, Shufan

BACKGROUNDDiabetic nephropathy (DN) is a diabetes mellitus (DM)-induced complication that poses high morbidity and mortality risks. The Astragalus and Salvia miltiorrhiza couplet medicines (AS) are commonly employed in DN clinical treatment in China, but their clinical efficacy and potential pharmacological mechanisms are yet to be evaluated.MATERIAL AND METHODSA meta-analysis of 15 studies involving 1,443 patients was conducted. Furthermore, network pharmacology predicted components and targets, which were verified by molecular docking and in vivo validation.RESULTSIn our meta-analysis, AS notably elevated clinical outcomes and renal function among patients with DN. Meanwhile, when the treatment duration exceeds 12 weeks, AS demonstrated a significant reduction in fasting blood glucose levels, indicating a time-dependent effect. Moreover, based on network pharmacology results, AS likely enhanced clinical outcomes by interacting with vital signaling pathways, including PI3K/Akt, MAPK, and NF-kappa B. Molecular docking studies have confirmed that PTGS2, the key therapeutic target of AS, can be closely combined with bioactive components GLY, quercetin, apigenin, and daidzein. Additionally, in vivo experiments have corroborated that AS can ameliorate renal function, UACR, and biomarkers associated with iron metabolism, such as GPX4, PTGS2, FTH1, and FTL1.CONCLUSIONThrough rigorous experimental validation, our study demonstrates AS's significant clinical efficacy in managing DN. Specifically, AS has been shown to enhance renal function, ameliorate renal fibrosis, and positively influence iron metabolism. Despite these promising outcomes, future research with a larger sample size must be conducted to further substantiate these findings.

31 Dec 2025·Animal Biotechnology

Quercetin alleviates metabolic-associated fatty liver disease by tuning hepatic lipid metabolism, oxidative stress and inflammation

Article

Author: Jiang, Ling ; Yi, Rong ; Chen, Huan ; Wu, Shuwu

The natural flavonoid quercetin, which exhibits a range of biological activities, has been implicated in liver disease resistance in recent research. In vivo study attesting to quercetin's protective effect against metabolic-associated fatty liver disease (MAFLD) is inadequate, however. Here, our investigation explored the potential benefits of quercetin in preventing MAFLD in C57BL/6 mice fed a high-fat diet (HFD). The results revealed that quercetin ameliorated the aberrant enhancement of body and liver weight. The hepatic histological anomalie induced by MAFLD were also mitigated by quercetin. HFD-induced imbalance in serum LDL, HDL, AST, ALT, TG, and LDH was mitigated by quercetin. Mechanically, we found that quercetin improved lipid metabolism by reducing lipogenesis proteins including ACC, FASN, and SREBP-1c and enhancing β-oxidation proteins including PPARα and CPT1A. In vitro study demonstrated that quercetin regulated hepatic lipid metabolism by targeting SREBP-1c and PPARα. Additionally, quercetin enhanced the antioxidant capacity in HFD-treated mice by downregulating Nrf2 and HO-1 expressions and upregulating SOD and GPX1 expressions. The hyper-activation of inflammation was also restored by quercetin via eliminating the phosphorylation of IκBα and NF-κB p65. Collectively, our observations highlight that quercetin exerts hepatoprotective properties in MAFLD mice by regulating hepatic lipid metabolism, oxidative stress and inflammatory response.

01 Dec 2025·Human & Experimental Toxicology

Activation of SIRT3/AMPK/mTOR-mediated autophagy promotes quercetin-induced ferroptosis in oral squamous cell carcinoma

Article

Author: Yang, Jia-Hui ; Wang, Jin ; Chen, Ling ; Xiong, Di

Introduction Quercetin has been reported to inhibit the growth of oral squamous cell carcinoma (OSCC), but the mechanism remains unclear. Therefore, our study aimed to investigate the involvement of sirtuin 3 (SIRT3) and the autophagy-dependent form of cell death, ferroptosis, in the pathogenesis of OSCC, and observe the impacts of quercetin on ferroptosis and SIRT3/AMPK/mTOR-mediated autophagy. Methods SIRT3 knock out or overexpressing SCC15 cell line was generated, treated with indicated drugs, and malondialdehyde (MDA) and ROS levels were measured. Roles of SIRT3 in regulating autophagy-mediated ferroptosis were assessed by immunoprecipitation and Western blotting. Results SIRT3 overexpression increased levels of MDA and ROS, reducing cell viability, and SIRT3 knockout produced the opposing effect. SIRT3 overexpression upregulated ATG16L1 expression and the conversion of LC3-Ⅰ to LC3-Ⅱ, triggering autophagy. Suppression of autophagy by ATG16L1 knockout impaired SIRT3-triggered ferroptosis. Use of an AMPK inhibitor antagonized the induction of ferroptosis by SIRT3 in SCC15 cells, indicating the involvement of the AMPK/mTOR pathway. Additionally, quercetin significantly increased the levels of SIRT3, p-AMPK, ATG16L1, and the ratio of LC3-Ⅱ/Ⅰ, but reduced cell viability and p-mTOR in SCC15 cells. Autophagy and AMPK inhibitors, or SIRT3 deletion significantly antagonized the impacts of quercetin on the autophagy-mediated ferroptosis in cancer cells. Discussion SIRT3 overexpression activated the AMPK/mTOR pathway and triggered ATG16L1-mediated autophagy, promoting ferroptosis in SCC15 cells, and we proposed that quercetin may be a promising therapeutic drug for OSCC.

News (Medical) associated with Quercetin

11 Jun 2024

·www.sciencedaily.com

How the immune system goes awry during space travel and the implications for human aging on earth

Researching the immune system in space could have payoffs for human aging on earth. Scientists have revealed how the lack of gravity affects the cells of the immune system at single cell resolution. As long as humans have been traveling into space, astronauts have experienced significant health effects from the extreme conditions of space flight, notably the reduction of gravity. Two Buck scientists led a team that has revealed for the first time how the lack of gravity affects the cells of the immune system at single cell resolution. As co-senior authors, along with Christopher E. Mason, PhD of Weill Cornell Medical College, Associate Professor David Furman, PhD and Associate Professor Daniel Winer, MD, published in the June 11, 2020 issue of Nature Communications an extensive survey of how gravity affects immune cells, and the identification of "space nutraceuticals" to counter aberrant effects of microgravity on these cells. "We show how simulated microgravity shapes immune cells and how the changes in force alter the cells' function at the single cell level," said Winer. "This level of resolution is new and exciting in understanding the effects of microgravity on cells." Using cells in simulated microgravity, combined with data from space flight from astronauts and mice on the International Space Station, the researchers created a complete picture of how the different cells of the immune system in the peripheral blood are shaped by reduced gravity. These cells include lymphocytes and monocytes, which are the main players in immunity. The study has potential implications for immune aging on Earth since the changes observed during aging resemble those captured during space travel. The team additionally outlines a pathway for identifying compounds that can reverse the effects of near zero gravity, and demonstrates that one of the compounds, quercetin, shows promise for mitigating the damage caused by spaceflight and during normal aging on the ground. "Our work provides a resource to better understand how and why the immune system changes in simulated microgravity and spaceflight," said Furman. "We also provide a way to develop countermeasures to maintain normal immunity under these harsh conditions." Astronauts in low earth orbit, such as on the International Space Station, suffer from immune system problems, especially infections, latent viruses reactivating, and skin sensitivity. These reactions occur even on short-term spaceflights. Previous studies using actual or simulated microgravity conditions have found impaired function of various immune cells. However, the fundamental mechanisms, genes, and pathways that explain immune dysfunction in microgravity were mostly unclear, the researchers said. They wanted to understand what was happening on a cellular level to explain the changes. The team, led by the study's co-first authors Buck postdoctoral researcher Fei Wu, PhD and graduate student Huixun Du, examined in depth how 25 hours of simulated microgravity affects the human peripheral blood mononuclear immune system, using samples from 27 healthy human donors between the ages of 20 and 46. To simulate an environment with almost no gravity, the team grew the cells inside of a Rotating Wall Vessel, a device developed by NASA to simulate microgravity conditions. To explore the changes caused by reduced gravity, the team used a number of techniques, including sequencing and super-resolution microscopy. They then validated their findings by comparing their data with other space studies done in humans and mice, including the JAXA (Cell-Free Epigenome study) mission, SpaceX's Inspiration 4 mission, NASA's Twins Study, and spleens from mice housed on the International Space Station. "Interestingly, changes in mechanical forces appear to orchestrate immune cell function," said Winer, whose interest in studying space medicine grew from him delving into the emerging field of mechanoimmunology, or how environmental forces affect immune cell function. Parts of astroimmunology are related to mechanoimmunolgy, but it is proving its own as a new field, he said, paving the way to better understand how to help the immune system survive in space. After unearthing several genes and biochemical pathways that are affected by microgravity, the team wanted to see if they could find any specific drugs or supplements that could protect the immune cells. To help them search, they used machine learning technology developed by Furman at the Buck, which can detect more than 2 million interactions between genes and different drugs and foods. They identified dozens of potential compounds and chose one, the plant pigment quercetin (often found in red onions, grapes, berries, apples and citrus fruits among others) to explore further since it is widely available as an antioxidant and anti-aging supplement. Quercetin turned out to reverse approximately 70 percent of the changes caused by lack of gravity and protected the cells from reactive oxygen species excess. "These findings define hallmarks of immune cell alteration in simulated microgravity, with correlation to spaceflight exposures in mice and humans," said Winer. "This work helps define avenues for future research in mechanoimmunology and astroimmunology and provides opportunities to develop countermeasures to maintain normal cellular function in space." Furman adds that this publication sets the standard for how to analyze the physiological changes that accompany space travel. "This is the first comprehensive study that provides the scientific community worldwide with an atlas to understand human biology in this extreme condition," he says. "The implications are huge, beyond humans in space," he adds. The researchers are excited to explore the parallel changes they are finding that occur in aging humans on the ground, and to use the knowledge to design interventions that can potentially reverse the immune dysfunction that accompanies aging.

05 Mar 2024

·www.prnewswire.com

Study Illustrates Zeropollution's Enhancing Skin's Resilience to Environmental Damage

New research reveals botanical blend's enhancement of complexion by inhibiting pollution-induced damage and inflammation. MADRID, March 5, 2024 /PRNewswire/ -- A new, preclinical study highlights the abilities of a beauty-from-within botanical-blend Zeropollution® to shield skin from the adverse effects of city pollution, especially from free radical damage on a cellular level. Continue Reading Study Illustrates Zeropollution’s Enhancing Skin’s Resilience to Environmental Damage (PRNewsfoto/Monteloeder, S.L.) Formulated by nutraceutical company Monteloeder, S.L., a subsidiary of SuanNutra, Zeropollution harnesses a medley of botanical extracts that includes lemon verbena (Lippia citriodora), rosemary (Rosmarinus officinalis), olive, (Olea europaea), and Japanese pagoda tree (Sophora japonica). This patented multi-herbal cosmeceutical has been crafted to synergistically strengthen the skin's protective barrier against environmental insults through an "inside out" approach. Living in a toxic world, people are becoming more mindful of the health consequences posed by air pollution, ultraviolet light, and chemicals not only upon skin function but also on overall wellbeing. Pollutants affect the skin on several levels. They can alter the skin barrier and skin microflora and increases oxidative stress, damaging and disrupting DNA. The study led by Laurent Peno-Mazzarino was published in the Journal of Current Issues in Molecular Biology in January 2024. Positive outcomes were observed in both ex vivo human skin explants and in in vitro models using human epidermal cells exposed to pollutants, including heavy metals and diesel particles condensed into an urban dust. These are the main components of "city pollution" particulates found in nearly every urban environment. The outcomes revealed several mechanisms of action underlying the protective effect of Zeropollution, including marked reductions in lipid peroxidation induced by pollutants. This encompasses reactive molecules generated by factors such as UV radiation, pollution, and other environmental stressors that can damage cells and tissues. By only the third day of the study total inhibition of these molecules was observed. The formula effectively suppressed the inflammatory response triggered by environmental pollution. Specifically, IL1-α inflammatory markers were reduced by almost 90%. Zeropollution also significantly reduced pollutant-induced production of reactive oxygen species (ROS) in human endothelial cells and lung tissue cells. In this study, Zeropollution successfully counteracted the adverse effects of urban dust on the heart rate of zebra fish embryos. Moreover, it demonstrated abilities to inhibit the overactivation of the aryl hydrocarbon receptor (AhR), another biological pathway of the pollutant stress response that causes inflammation and skin damage. "This study underscores its beneficial effects on guarding the skin from pollution as supported by in vitro models," enthuses Nuria Caturla, PhD, Chief R&D Officer for Monteloeder. "While results of previous clinical studies endorsed Zeropollution's antioxidant and anti-aging effects, this preclinical research delves deeper into the botanical compound's molecular mechanisms." "Zeropollution possesses profound antioxidant and protective properties, as proven by its ability to reduce free-radical damage, inflammation and lipid peroxidation, while also offering protection against heavy metals," adds Caturla. In a previous clinical trial on 100 women volunteers living in polluted urban zones, supplementation with Zeropollution was linked to increased skin elasticity and firmness, strengthened skin barrier function, and skin radiance. Antioxidant status measured was also improved. "The botanical blend was uniquely crafted to fortify the skin's natural defences against external insults and nourish it from within," continues Caturla. "This study unveils Zeropollution's antioxidant potential beyond skin health, suggesting cardiopulmonary and endothelial benefits. This broadens its application spectrum beyond nutricosmetics and aligns with the consumer belief that help for a beautiful complexion can emanate from the inside." The proprietary formula comprises a polyphenol-enriched herbal blend containing a diverse array of phytochemical compounds sourced from various botanicals. This design is inspired by extensive scientific literature advocating that the use of multiple antioxidants as opposed to a high dose of a single antioxidant could be more effective owed to their complementary or synergistic effects. Zeropollution is built around the company's prized lemon verbena ingredient which stars in many of Monteloeder's portfolio of branded botanical formulations. The formula is standardized to several active compounds and quantified by HPLC-DAD analysis. These include hydroxytyrosol, verbascoside, oleuropein, rosemary diterpenes, and quercetin. All of which possess antioxidant and anti-inflammatory properties. Zeropollution's composition houses verbascosides derived from lemon verbena with a specific role in safeguarding pulmonary cells by enhancing the activity of antioxidant enzymes while inhibiting activity of inflammatory mediators and signaling pathways. Zeropollution can be delivered in various formats, including "shots," soft gels, capsules, effervescent tablets, as well as in functional foods and beverages. Designed to be taken internally, Zeropollution is tailored for all beauty-from-within applications, responding to consumer demand for holistic solutions that embrace the fusion of beauty, health, and wellness. Visit us at SupplySide East, April 16-17, booth #4327 About Monteloeder: Monteloeder contributes cutting-edge innovation and scientific rigor to the development of botanical health ingredients, featuring proprietary patented products supported by clinical studies. The company's portfolio has garnered international accolades in Health & Wellness, Women's Health, and Beauty from Within. Monteloeder is a subsidiary of SUANNUTRA, which boasts a rich heritage of more than 125 years of combined experience in the European nutraceutical sector. For more information, contact: Company contact: Monteloeder, S.L., a subsidiary of SuanNutra Mariana Ortega Product Manager E-mail: [email protected] Website: Photo - SOURCE Monteloeder, S.L.

Clinical Result

25 Jan 2024

·www.prnewswire.com

Zynamite® PX Shown to Boost Performance in High Level Athletes Within One Hour

New Study Demonstrated that National-Level Basketball Players in Greece were Faster and had Significantly Reduced Perceived Exertion MORRISTOWN, N.J., Jan. 25, 2024 /PRNewswire/ -- PLT Health Solutions, Inc announced that a new double-blind, crossover study on award-winning Zynamite® PX showed significant performance improvements in high-intensity exercise for high-level athletes. Published in the journal Nutrients in January 2024, the study, conducted by academic researchers in Greece, examined the effects of a single dose of Zynamite PX on top Greek national basketball players during a basketball exercise stimulation test (BEST). Participants in the supplement group were faster, showing a statistically significant improvement in mean circuit lap time compared to those in the placebo group. The Zynamite PX group also showed a significant reduction in their subjective rating of perceived exertion, which is used to assess muscular effort and fatigue. Zynamite PX is a synergistic combination of a Mangifera indica extract and Sophora japonica extract (standardized to 50% quercetin) that offers a unique set of benefits in active/sports nutrition products. The ingredient is manufactured by Nektium Pharma, S.L. and marketed exclusively by PLT in the United States, Mexico, and Canada. Continue Reading Published in the journal Nutrients in January 2024, the study, conducted by academic researchers in Greece, examined the effects of a single dose of Zynamite PX on top Greek national basketball players during a basketball exercise stimulation test (BEST). Participants in the supplement group were faster, showing a statistically significant improvement in mean circuit lap time compared to those in the placebo group. This is the second study that has shown significant performance improvements by athletes just one hour after supplementing with Zynamite PX - the previous study relating to improved power. This fast-acting performance improvement opens up a new range of commercial opportunities for sports nutrition consumer products companies. According to Devin Stagg, Chief Operating Officer at PLT Health Solutions, the new study adds to knowledge on Zynamite PX as fast-acting support for enhanced exercise performance. "This is the second study that has shown significant performance improvements by athletes just one hour after supplementing with Zynamite PX – the previous study relating to improved power. This fast-acting performance improvement opens up a new range of commercial opportunities for sports nutrition consumer products companies," he said. "We are grateful and congratulate the team of scientists who conducted this exciting study," he said. Study Shows Improved Performance for Elite Athletes The study featured 38 male basketball players from the top three national teams in Greece. Both the Zynamite group and the placebo group were administered supplements one hour prior to testing. The BEST involved a circuit-based activity encompassing various movement distances. Before and after the BEST researchers measured heart rate, circuit time, sprint time, blood lactate levels, and the subjective ratings of muscle soreness and perceived exertion. Findings showed significant improvements in mean circuit time and perceived exertion for the Zynamite group. Zynamite PX: More Power. One Dose. One Hour. A 2019 randomized, double-blind, placebo-controlled crossover study was conducted to determine whether a single dose of Zynamite PX administered one hour before exercise would increase cycle-sprint performance. Subjects performed three Wingate sprint tests interspaced by 4 minutes and a final 15-second sprint after induced ischemia (blood flow restriction, which simulates exhaustion). Peak power was improved by 3.8% in one hour compared to placebo in subjects who took just one dose of Zynamite PX. According to Jeremy Appleton, ND, Director of Medical & Scientific Affairs, the extremely rapid increases in performance and recovery after limited use of Zynamite PX are eye-opening. "An increase in peak power of 3.8% might not seem impressive at first, but it is important to remember that we are comparing it to other studies where power results were achieved after much longer periods of supplementation. This offers a new type of benefit package to sports nutrition formulators we have not seen before," he said. The new study, 'Effects of a Singular Dose of Mangiferin-Quercetin Supplementation on Basketball Performance: A Double-Blind Crossover Study of High-Level Male Players,' can be viewed here: . For more information on this ingredient, visit . SOURCE PLT Health Solutions

Clinical ResultClinical Study

100 Deals associated with Quercetin

External Link

KEGG	Wiki	ATC	Drug Bank
-	Quercetin	-	DB04216

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Thromboembolism	Phase 3	-	Quercegen Pharmaceuticals LLC	-
Emphysema	Phase 2	United States	Quercegen Pharmaceuticals LLC	01 Nov 2023
Pulmonary Disease, Chronic Obstructive	Phase 2	United States	Quercegen Pharmaceuticals LLC	01 Nov 2023
stress oxidative	Phase 2	United States	Quercegen Pharmaceuticals LLC	01 Nov 2023
Atherosclerosis	Phase 2	Ireland	-	-
Cardiovascular Diseases	Phase 2	China	-	-
Neoplasms	Phase 2	United Kingdom	-	-
Prostatitis	Phase 2	United States	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04063124 (SToMP-AD, CTgov)	Phase 1/2	Alzheimer Disease	5	Dasatinib+Quercetin	ojcxjehdfq(vjufpsafbh) = wohrpzuawc tezflgunbp (rzofnhlgua, mhifhsevlx - hzdmyxqcbs) View more	-	06 Mar 2023
UEGW2022	Not Applicable	Metabolic dysfunction-associated steatotic liver disease	-	Quercetin tablets 40mg	jclnncpvsh(rvuwohkjsf) = tzuexwljil iasipfrouq (ewsbtzuxau )	-	09 Oct 2022
				QUERCETIN (EASLâEASDâEASO Clinical Practice Guidelines)	jclnncpvsh(rvuwohkjsf) = fwoxeuikfm iasipfrouq (ewsbtzuxau )
Senolytics in Idiopathic Pulmonary Fibrosis (ATS2022)	Not Applicable	Idiopathic Pulmonary Fibrosis	12	Dasatanib 100 mg/d; Quercetin 1250 mg/d	vdvwxpqmwl(jsjsysjurq) = mkvtjgyrdm pcufwgtiln (zvewrkwxuw ) View more	Positive	15 May 2022
				Placebo	vdvwxpqmwl(jsjsysjurq) = kqizrdgclz pcufwgtiln (zvewrkwxuw ) View more
IRCT20200419047128N2 (Pubmed \| Eur J Pharmacol) Manual	Phase 3	COVID-19	60	remdesivir or favipiravir+quercetin	ftizwhghwa(maqgbohcjd) = hyspxerfvp yahbxwfkfd (snyxastnbc ) View more	Superior	05 Jan 2022
				remdesivir or favipiravir	ftizwhghwa(maqgbohcjd) = norxzvhnps yahbxwfkfd (snyxastnbc ) View more
2021 ARVO Annual Meeting (ARVO2021)	Not Applicable	Geographic Atrophy	10	Oral supplementation with resveratrol, quercetin, and curcumin (RQC)	(ueqxsiczvt) = ndlctsjplj ytzfwksnyw (opalhyekfb, 0.10)	Positive	01 Jun 2021
NCT01722669 (PK/PD, CTgov)	Early Phase 1	Thrombophilia	38	Quercetin (Quercetin 500 mg (ARM A1))	(jabqziqxkn) = hvryxchqsy fsarncbgxo (hmlpnwjvrt, awbglizspq - jhgtkzincy) View more	-	12 Oct 2020
				Isoquercetin (Isoquercetin 500 mg (ARM B1))	(jabqziqxkn) = rsjcajdkdb fsarncbgxo (hmlpnwjvrt, rehqodpwop - stbncqdaoj) View more
ESC2019	Not Applicable	Acute decompensated heart failure	-	Quercetin Q1	sjlngvoitd(opbqpmcbqn) = ezjfdczzek wcjrcophca (blofqvmwjh ) View more	Positive	26 May 2019
				Quercetin Q2	sjlngvoitd(opbqpmcbqn) = bcwemdvwea wcjrcophca (blofqvmwjh ) View more
ESC2018	Not Applicable	ST Elevation Myocardial Infarction	268	Quercetin	mlnsavmimp(ivhytyjvxe) = jornmmmysd gjfmefufby (cuxmpiwiwj )	-	27 Aug 2018
				Standard therapy	mlnsavmimp(ivhytyjvxe) = gozxzzjxrf gjfmefufby (cuxmpiwiwj )
ESC2018	Not Applicable	ST Elevation Myocardial Infarction	-	Intravenous Quercetin	sklohbrcjy(zchahrjtlt) = uhcardzjoh kvuqmbynum (mxontfwent )	-	26 Aug 2018
				quercetin	sklohbrcjy(zchahrjtlt) = sfpmgpufgd kvuqmbynum (mxontfwent )
NCT01708278 (Quercetin, CTgov)	Phase 1	Pulmonary Disease, Chronic Obstructive	9	Quercetin (Quercetin 1-Cohort 1)	xadkcocggm(irgpxryrst) = wpdimehhyt rorfveaguy (axzihcxkmo, pprsmjjbhj - qhwrsabeqo) View more	-	26 Dec 2016
				Quercetin (Quercetin 2-Cohort 2)	xadkcocggm(irgpxryrst) = wxmdnvhzep rorfveaguy (axzihcxkmo, vvcgvglbdv - vrkrpdhvpz) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis